JP2021517164A5 - - Google Patents

Info

Publication number
JP2021517164A5
JP2021517164A5 JP2020570407A JP2020570407A JP2021517164A5 JP 2021517164 A5 JP2021517164 A5 JP 2021517164A5 JP 2020570407 A JP2020570407 A JP 2020570407A JP 2020570407 A JP2020570407 A JP 2020570407A JP 2021517164 A5 JP2021517164 A5 JP 2021517164A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517164A (ja
JP7849948B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020810 external-priority patent/WO2019173380A1/en
Publication of JP2021517164A publication Critical patent/JP2021517164A/ja
Publication of JP2021517164A5 publication Critical patent/JP2021517164A5/ja
Priority to JP2024014959A priority Critical patent/JP2024032976A/ja
Priority to JP2026017947A priority patent/JP2026074199A/ja
Application granted granted Critical
Publication of JP7849948B2 publication Critical patent/JP7849948B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570407A 2018-03-05 2019-03-05 アデノシン受容体アンタゴニストおよびその使用 Active JP7849948B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024014959A JP2024032976A (ja) 2018-03-05 2024-02-02 アデノシン受容体アンタゴニストおよびその使用
JP2026017947A JP2026074199A (ja) 2018-03-05 2026-02-05 アデノシン受容体アンタゴニストおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862638737P 2018-03-05 2018-03-05
US62/638,737 2018-03-05
US201862688088P 2018-06-21 2018-06-21
US62/688,088 2018-06-21
PCT/US2019/020810 WO2019173380A1 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024014959A Division JP2024032976A (ja) 2018-03-05 2024-02-02 アデノシン受容体アンタゴニストおよびその使用

Publications (3)

Publication Number Publication Date
JP2021517164A JP2021517164A (ja) 2021-07-15
JP2021517164A5 true JP2021517164A5 (cg-RX-API-DMAC10.html) 2022-04-01
JP7849948B2 JP7849948B2 (ja) 2026-04-22

Family

ID=67847428

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020570407A Active JP7849948B2 (ja) 2018-03-05 2019-03-05 アデノシン受容体アンタゴニストおよびその使用
JP2024014959A Withdrawn JP2024032976A (ja) 2018-03-05 2024-02-02 アデノシン受容体アンタゴニストおよびその使用
JP2026017947A Pending JP2026074199A (ja) 2018-03-05 2026-02-05 アデノシン受容体アンタゴニストおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024014959A Withdrawn JP2024032976A (ja) 2018-03-05 2024-02-02 アデノシン受容体アンタゴニストおよびその使用
JP2026017947A Pending JP2026074199A (ja) 2018-03-05 2026-02-05 アデノシン受容体アンタゴニストおよびその使用

Country Status (12)

Country Link
US (3) US20210040097A1 (cg-RX-API-DMAC10.html)
EP (2) EP4364727A3 (cg-RX-API-DMAC10.html)
JP (3) JP7849948B2 (cg-RX-API-DMAC10.html)
KR (1) KR102754522B1 (cg-RX-API-DMAC10.html)
CN (1) CN112218867B (cg-RX-API-DMAC10.html)
AU (2) AU2019232736B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020018158A2 (cg-RX-API-DMAC10.html)
ES (1) ES2975753T3 (cg-RX-API-DMAC10.html)
IL (1) IL277144B2 (cg-RX-API-DMAC10.html)
MX (1) MX2020009286A (cg-RX-API-DMAC10.html)
SG (1) SG11202008611UA (cg-RX-API-DMAC10.html)
WO (1) WO2019173380A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7849948B2 (ja) 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用
BR112023002180A2 (pt) * 2020-08-07 2023-05-02 Teon Therapeutics Inc Terapia de combinação com antagonistas de receptor de adenosina
EP4211135A1 (en) * 2020-09-04 2023-07-19 Teon Therapeutics, Inc. Cocrystals of an adenosine a2b receptor antagonist
TW202313612A (zh) 2021-06-04 2023-04-01 美商天恩治療有限公司 腺苷ab受體拮抗劑的固體形式
TW202327612A (zh) * 2021-09-10 2023-07-16 美商天恩治療有限公司 使用腺苷受體拮抗劑之改良療法
EP4554943A1 (en) * 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2026035860A1 (en) 2024-08-07 2026-02-12 Teon Therapeutics, Inc. Formulations of adenosine receptor antagonist

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466811A (en) * 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
EP1075472A1 (en) * 1998-04-15 2001-02-14 Warner-Lambert Company Prodrugs of benzofuranylmethyl carbamate nk 1? antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
GEP20074230B (en) * 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
WO2004106337A1 (en) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
PL1789053T3 (pl) * 2004-09-01 2012-12-31 Gilead Sciences Inc Sposób gojenia się rany wykorzystujący antagonistów receptora adenozynowego A2B
EP2311462A1 (en) 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
CA2646333C (en) 2006-03-17 2014-06-17 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
WO2008066627A2 (en) 2006-10-24 2008-06-05 Board Of Regents, The University Of Texas System Adenosine signaling in diagnosis, treatment and prevention of priapism and erectile dysfunction
WO2009088518A1 (en) 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
WO2009157938A1 (en) 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
KR20130088834A (ko) 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 a2b 아데노신 수용체 길항제의 용도
EP2616470B1 (en) * 2010-09-13 2016-10-12 Advinus Therapeutics Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2012170209A2 (en) * 2011-05-23 2012-12-13 Nectid, Inc. Benzofuran-2 carboxamide compounds
US10117868B2 (en) 2011-10-25 2018-11-06 Case Western Reserve University Systems pharmacology for treating ocular disorders
US10702476B2 (en) 2017-08-14 2020-07-07 Phosphorex, Inc. Microparticle formulations of adenosine receptor antagonists for treating cancer
KR20200103018A (ko) 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도
JP7849948B2 (ja) 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用

Similar Documents

Publication Publication Date Title
JP2024050527A5 (cg-RX-API-DMAC10.html)
JP2022512482A5 (cg-RX-API-DMAC10.html)
CN113614080A (zh) Kras g12c抑制剂化合物及其用途
KR101927114B1 (ko) 치료 화합물 및 조성물
JP6269862B2 (ja) 三環性スピロ化合物
JP2021511331A5 (cg-RX-API-DMAC10.html)
JP2022532706A5 (cg-RX-API-DMAC10.html)
JP2010506854A5 (cg-RX-API-DMAC10.html)
JP2022544714A5 (cg-RX-API-DMAC10.html)
JP2011509309A5 (cg-RX-API-DMAC10.html)
WO2021078274A1 (zh) 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
TW201431865A (zh) 硼酸衍生物及其治療用途
EP3992176B1 (en) Ep2 antagonist
JP6672296B2 (ja) 強力なγ−セクレターゼモジュレータ
CN102361868A (zh) 作为1-磷酸-鞘氨醇激动剂的吡唑-1,2,4-噁二唑衍生物
JP2023516235A5 (cg-RX-API-DMAC10.html)
JP2022119852A5 (cg-RX-API-DMAC10.html)
JP2022509206A5 (cg-RX-API-DMAC10.html)
JP2020518571A5 (cg-RX-API-DMAC10.html)
JP2019535644A (ja) ジヒドロピリミジン化合物並びにその調製方法及び使用
CN111278809A (zh) 二环砜类和亚砜类、以及其使用方法
JP2024032976A (ja) アデノシン受容体アンタゴニストおよびその使用
TW202241399A (zh) Ep受體拮抗藥與免疫檢查點抑制藥及/或ep受體拮抗藥之組合
CN107531634A (zh) 作为wnt信号通路抑制剂的3‑氨基甲酰基苯基‑4‑甲酰胺和间苯二甲酰胺衍生物
JP2022552019A5 (cg-RX-API-DMAC10.html)